Distribution of Celltrion's revenue Q2 2024, by product

Published by Statista Research Department, Sep 19, 2024

During the second quarter of 2024, around 88.5 percent of Celltrion's revenue stemmed from its bioproducts, most notably Remsima IV, an anti-inflammatory used to treat several immune system conditions such as Crohn's disease.

Distribution of Celltrion's revenue in 2nd quarter of 2024, by product

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

August 2024

Region

South Korea

Survey time period

Q2 2024

Supplementary notes

Values may not add up to 100 percent due to rounding.

* Includes Bevacizumab, Yuflyma, Zymfentra, Remsima SC, Herzuma, Truxima, and Remsima IV/Inflectra.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Pharmaceutical industry in Spain "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Pharmaceutical industry in Spain

Overview

6

International trade

6

Pharmaceutical sales

6

Pharmaceutical expenditure of the National Health System

6

Research and development

6

Company rankings

6

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Pharmaceutical market in the PhilippinesInsurance industry in the PhilippinesDemographics of the PhilippinesCoronavirus (COVID-19) pandemic in the PhilippinesHealthcare in the Philippines
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.